Paragon Care Limited (ASX:PGC): FY26 Revenue, Integration Progress and Healthcare Distribution Updates

Aditi Sarkar

19 October 2026 03:33 PM AEDT

Paragon Care Limited (ASX:PGC): FY26 Revenue, Integration Progress and Healthcare Distribution Updates

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Paragon Care Limited (ASX:PGC) reported approximately AUD 3.7 billion in underlying FY26 revenue.
FY26 underlying EBITDA reached AUD 97.2 million, according to the company’s investor information.
The company reported approximately AUD 26 million in underlying net profit after tax for FY26.
September announcements covered audited results and an on-market share buy-back.

Paragon Care Limited (ASX:PGC) supplies pharmaceuticals, medical consumables, equipment and diagnostic products to healthcare customers across Australia and other Asia-Pacific markets. Its financial year ended June 2026 followed a period of business integration after the 2024 combination of Paragon Care and Clifford Hallam Healthcare. Recent disclosures describe changes to its distribution activities, the completion of major integration work and the company’s financial results. Together, these developments provide context for reviewing its operating mix, underlying earnings and financial exposures.

At the time of writing on 19 October 2026, the indicated trading-session price for Paragon Care was AUD 0.150, up 3.45% according to the price snapshot supplied for the article.

Company Business

ParagonCare operates as a healthcare wholesaler, distributor and manufacturer. Its range spans pharmaceutical wholesale and dispensary supplies, hospital consumables, diagnostic reagents, medical devices and capital equipment, as well as complementary medicines and nutritional products. Customers include pharmacies, hospitals, pathology laboratories, primary-care providers, aged-care facilities and specialist clinicians.

Its operations extend beyond Australia into New Zealand and a range of Asian markets, with local businesses and distribution capabilities supporting different clinical categories. The portfolio includes diagnostic instruments and blood-bank reagents, imaging products, specialist surgical equipment and contract logistics services. Such breadth makes execution dependent on procurement arrangements, inventory availability, warehousing performance and ongoing customer relationships.

Recent Development

In September 2026, ParagonCare published its annual report and audited FY26 financial results. The company also announced an on-market share buy-back in mid-September, followed by the related regulatory notification. Those announcements sit alongside its August preliminary results and investor presentation, which addressed the performance of its combined healthcare distribution operations.

During FY26, the business continued work on the integration of its healthcare distribution operations following the Clifford Hallam transaction. At the half-year stage, the company reported commencement of activity at its purpose-built Willawong distribution centre in Brisbane, as well as investments and acquisitions intended to broaden its product and customer coverage. It also referred to an Australian Defence supply contract covering pharmaceuticals, medical consumables and dental products.

A separate operational issue involved Infinity Pharmacy Group. The company reported in its half-year release that it had taken a full provision against the related debt exposure and ceased trading with the group in March 2025. Its handling of that exposure remains relevant when examining receivables quality and the composition of pharmacy wholesale sales.

Financial Performance and Sector Context

The company’s FY26 investor information reports approximately AUD 3.7 billion of underlying revenue, AUD 97.2 million of underlying EBITDA and AUD 26 million of underlying net profit after tax. These are underlying performance measures rather than interchangeable measures of statutory profit or operating cash generation, and readers should distinguish between them when reviewing the annual report.

For the six months ended 31 December 2025, ParagonCare reported revenue of AUD 1,904.9 million, compared with AUD 1,850.4 million a year earlier, an increase of 2.9%. Underlying EBITDA increased from AUD 47.5 million to AUD 49.0 million, while underlying net profit after tax was AUD 13.3 million, compared with AUD 13.2 million. The corresponding underlying EBITDA margin was 2.57%.

At December 2025, the company reported net debt of AUD 287.5 million, compared with AUD 226.6 million in June 2025, while its pro-forma net debt-to-EBITDA ratio increased from 2.26 times to 2.81 times. These half-year balance-sheet figures provide historical context and should not be mistaken for the June 2026 audited closing position.

Healthcare distribution is affected by supply contracts, customer purchasing volumes, freight and warehousing costs, the reliability of clinical product supply and changes in reimbursement or procurement arrangements. ParagonCare’s pharmacy exposure also places importance on wholesale customer credit quality, while equipment and diagnostics businesses have different sales cycles from frequently purchased consumables.

Risks to Consider

Relevant risks include integration costs, supply-chain interruptions, customer concentration, margin pressure and working-capital demands. The previously disclosed Infinity Pharmacy Group provision highlights the potential effect of counterparty credit problems. Debt servicing and the timing of cash collection also warrant attention, particularly where inventory requirements or acquisitions affect the balance sheet. Any buy-back expenditure must be considered in the context of liquidity and other capital requirements.

What to Watch Next

Future company disclosures can clarify whether integration benefits are reflected in operating costs, inventory management and cash conversion. Other points include the contribution from recently established distribution facilities, contract execution, progress in newer clinical categories and developments affecting the Infinity exposure. The next formal reporting period will also provide updated statutory and underlying earnings, cash-flow data, borrowing levels and management commentary.

Key Insights

ParagonCare’s FY26 information points to a large regional healthcare distribution operation with underlying revenue of approximately AUD 3.7 billion and underlying EBITDA of AUD 97.2 million. The 2024 combination, network changes, contract activity and pharmacy credit exposure remain important parts of the operating picture. Subsequent results will show how these matters translate into reported earnings, working capital and cash generation.

FAQs

Q:What does Paragon Care Limited do?

A:It distributes pharmaceuticals, medical equipment, devices, consumables and diagnostic products, and undertakes related healthcare manufacturing and service activities.

Q:What was ParagonCare’s FY26 underlying revenue?

A:The company’s investor information reports approximately AUD 3.7 billion in underlying revenue for FY26.

Q:What was its FY26 underlying EBITDA?

A:ParagonCare reported AUD 97.2 million in underlying EBITDA for the year ended June 2026.

Q:What significant operational issue did ParagonCare disclose?

A:It disclosed a provision relating to its exposure to Infinity Pharmacy Group and an exit from associated wholesale trading.

Q:What developments may be monitored next?

A:Subsequent financial reports, operating cash flow, net debt, integration execution, distribution performance and customer credit exposure.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.